{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T10:27:30Z","timestamp":1756463250385,"version":"3.37.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T00:00:00Z","timestamp":1627862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T00:00:00Z","timestamp":1627862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Braz J Microbiol"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s42770-021-00582-4","type":"journal-article","created":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T01:02:32Z","timestamp":1627866152000},"page":"1967-1979","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["PK\/PD modeling of daptomycin against MRSA and MRSE and Monte Carlo simulation for bacteremia treatment"],"prefix":"10.1007","volume":"52","author":[{"given":"Bruna","family":"Menezes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izabel","family":"Alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keli","family":"Staudt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Betina","family":"Beltrame","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lessandra","family":"Michelin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bibiana Verlindo","family":"de Ara\u00fajo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7102-9204","authenticated-orcid":false,"given":"Leandro","family":"Tasso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,2]]},"reference":[{"key":"582_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ijid.2017.05.010","volume":"61","author":"P Ayau","year":"2017","unstructured":"Ayau P, Bardossy AC, Sanchez G, Ortiz R, Moreno D, Hartman P et al (2017) Risk factors for 30-day mortality in patients with methicillin-resistant Staphylococcus aureus bloodstream infections. Int J Infect Dis 61:3\u20136","journal-title":"Int J Infect Dis"},{"key":"582_CR2","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/QCO.0b013e328337fecb","volume":"23","author":"GYC Cheung","year":"2010","unstructured":"Cheung GYC, Otto M (2010) Understanding the significance of Staphylococcus epidermidis bacteremia in babies and children. Curr Opin Infect Dis 23:208\u2013216","journal-title":"Curr Opin Infect Dis"},{"key":"582_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.rmu.2015.10.003","volume":"17","author":"A Mart\u00ednez-Mel\u00e9ndez","year":"2015","unstructured":"Mart\u00ednez-Mel\u00e9ndez A, Morf\u00edn-Otero R, Villarreal-Trevi\u00f1o L, Gonz\u00e1lez-Gonz\u00e1lez G, Llaca-D\u00edaz J, Rodr\u00edgues-Noriega E et al (2015) Staphylococcal cassette chromosome mec (SCC mec) in coagulase negative staphylococci. Medicina Universit\u00e1ria 17:229\u2013233","journal-title":"Medicina Universit\u00e1ria"},{"key":"582_CR4","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.coph.2006.07.001","volume":"6","author":"DL Paterson","year":"2006","unstructured":"Paterson DL (2006) Clinical experience with recently approved antibiotics. Curr Opin Pharmacol 6:486\u2013490","journal-title":"Curr Opin Pharmacol"},{"key":"582_CR5","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1128\/AAC.01011-09","volume":"54","author":"C Garc\u00eda-de-la-M\u00e0ria","year":"2010","unstructured":"Garc\u00eda-de-la-M\u00e0ria C, Marco F, Armero Y, Soy D, Moreno A, Del R\u00edo A et al (2010) Daptomycin is effective for treatment of experimental endocarditis due to methicillin-resistant and glycopeptide \u2013 intermediate Staphylococcus epidermidis. Antimicrob Agents Chemother 54:2781\u20132786","journal-title":"Antimicrob Agents Chemother"},{"key":"582_CR6","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1086\/420818","volume":"38","author":"RD Arbeit","year":"2004","unstructured":"Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI (2004) The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 38:1673\u20131681","journal-title":"Clin Infect Dis"},{"key":"582_CR7","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1056\/NEJMoa053783","volume":"355","author":"VG Fowler Jr","year":"2006","unstructured":"Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW et al (2006) Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 355:653\u2013665","journal-title":"N Engl J Med"},{"key":"582_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1093\/cid\/cir764","volume":"54","author":"CL Moore","year":"2012","unstructured":"Moore CL, Osaki-Kiyan P, Haque NZ, Perri MB, Donabedian S, Zervos MJ (2012) Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case- control study. Clin Infect Dis 54:51\u201358","journal-title":"Clin Infect Dis"},{"key":"582_CR9","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1093\/cid\/cit112","volume":"56","author":"KP Murray","year":"2013","unstructured":"Murray KP, Zhao JJ, Davis SL, Kullar R, Kaye KS, Lephart P et al (2013) Early use of daptomycin versus vancomycin for methicillin resistant Staphylococcus aureus bacteremia with vancomycin MIC 1 mg\/L: a matched cohort study. Clin Infect Dis 56:1562\u20131569","journal-title":"Clin Infect Dis"},{"key":"582_CR10","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12866-016-0838-9","volume":"16","author":"S Foerster","year":"2016","unstructured":"Foerster S, Unemo M, Hathaway LJ, Low N, Althaus CL (2016) Time-kill curve analysis and pharmacodynamic modelling for in vitro evaluation of antimicrobials against Neisseria gonorrhoeae. BMC Microbiol 16:216\u2013227","journal-title":"BMC Microbiol"},{"issue":"2","key":"582_CR11","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1128\/AAC.48.2.369-377.2004","volume":"48","author":"M Mueller","year":"2004","unstructured":"Mueller M, Pe\u00f1a A, Derendorf H (2004) Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrob Agents Chemother 48(2):369\u2013377","journal-title":"Antimicrob Agents Chemother"},{"key":"582_CR12","doi-asserted-by":"crossref","unstructured":"Cristinacce A, Wright JG, Macpherson M, Iaconis J, Das S (2021) Comparing probability of target attainment against Staphylococcus aureus for ceftaroline fosamil, vancomycin, daptomycin, linezolid, and ceftriaxone in complicated skin and soft tissue infection using pharmacokinetic\/pharmacodynamic models. Diagn Microbiol Infect Dis 99 (4): 115292","DOI":"10.1016\/j.diagmicrobio.2020.115292"},{"key":"582_CR13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1128\/AAC.48.1.63-68.2004","volume":"48","author":"N Safdar","year":"2004","unstructured":"Safdar N, Andes D, Craig WA (2004) In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother 48:63\u201368","journal-title":"Antimicrob Agents Chemother"},{"key":"582_CR14","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.1128\/AAC.47.11.3561-3566.2003","volume":"47","author":"J Alder","year":"2003","unstructured":"Alder J, Li T, Yu D, Morton L, Silverman J, Zhang XX et al (2003) Analysis of daptomycin efficacy and breakpoint standards in a murine model of Enterococcus faecalis and Enterococcus faecium renal infection. Antimicrob Agents Chemother 47:3561\u20133566","journal-title":"Antimicrob Agents Chemother"},{"key":"582_CR15","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1097\/01.inf.0000094940.81959.14","volume":"22","author":"JS Bradley","year":"2003","unstructured":"Bradley JS, Dudley MN, Drusano GL (2003) Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation. Pediatr Infect Dis J 22:982\u2013992","journal-title":"Pediatr Infect Dis J"},{"key":"582_CR16","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1517\/17425250902913808","volume":"5","author":"D Czock","year":"2009","unstructured":"Czock D, Markert C, Hartman B, Keller F (2009) Pharmacokinetics and pharmacodynamics of antimicrobial drugs. Expert Opinion Drug Metabob Toxicol 5:475\u2013487","journal-title":"Expert Opinion Drug Metabob Toxicol"},{"key":"582_CR17","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.ijantimicag.2003.10.012","volume":"23","author":"Q Liu","year":"2004","unstructured":"Liu Q, Rand K, Derendorf H (2004) Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin-tazobactam combinations. Int J Antimicrob Agents 23:494\u2013497","journal-title":"Int J Antimicrob Agents"},{"key":"582_CR18","first-page":"117","volume":"74","author":"N Gr\u00e9goire","year":"2019","unstructured":"Gr\u00e9goire N, Marchand S, Ferrandi\u00e8re M, Lasocki S, Seguin P et al (2019) Population pharmacokinetics of daptomycin in critically ill patients with various degrees of renal impairment. J Antimicrob Chemother 74:117\u2013125","journal-title":"J Antimicrob Chemother"},{"key":"582_CR19","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/j.1469-0691.2006.01455.x","volume":"12","author":"EUCAST Steering Committee","year":"2006","unstructured":"EUCAST Steering Committee (2006) EUCAST technical note on daptomycin. Clin Microbiol Infect 12:599\u2013601","journal-title":"Clin Microbiol Infect"},{"key":"582_CR20","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1128\/AAC.45.3.845-851.2001","volume":"45","author":"A Louie","year":"2001","unstructured":"Louie A, Kaw P, Liu W, Jumbe N, Miller MH, Drusano GL (2001) Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother 45:845\u2013851","journal-title":"Antimicrob Agents Chemother"},{"key":"582_CR21","unstructured":"Clinical and Laboratory Standards Institute (2014) Performance standards for antimicrobial susceptibility testing: twenty fourth informational supplement, vol. M100- S24. CLSI, Wayne, PA."},{"key":"582_CR22","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ijantimicag.2013.06.006","volume":"42","author":"A Di Paolo","year":"2013","unstructured":"Di Paolo A, Tascini C, Polillo M, Gemignani G, Nielsen EI, Bocci G et al (2013) Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections. Intern J Antimicrob Agents 42:250\u2013255","journal-title":"Intern J Antimicrob Agents"},{"key":"582_CR23","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1128\/AAC.00247-06","volume":"50","author":"M Benvenuto","year":"2006","unstructured":"Benvenuto M, Benziger DP, Yankelev S, Vigliani G (2006) Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 50:3245\u20133249","journal-title":"Antimicrob Agents Chemother"},{"key":"582_CR24","unstructured":"EUCAST. 2021. Available at: http\/\/ www.eucast.org\/clinical_breakpoint (last accessed 19 may 2021)."},{"key":"582_CR25","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ijantimicag.2011.03.006","volume":"38","author":"G Wu","year":"2011","unstructured":"Wu G, Abraham T, Rapp J, Vastey F, Saad N, Balmir E (2011) Daptomycin: evaluation of a high-dose treatment strategy. Intern J Antimicrob Agents 38:192\u2013196","journal-title":"Intern J Antimicrob Agents"},{"key":"582_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-0711-9-9","volume":"9","author":"M Duah","year":"2010","unstructured":"Duah M (2010) Daptomycin for methicillin-resistant Staphylococcus epidermidis native-valve endocarditis: a case report. Ann Clin Microbiol Antimicrob 9:1\u20134","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"582_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/phar.1220","volume":"33","author":"R Kullar","year":"2013","unstructured":"Kullar R, Davis SL, Kaye KS, Levine DP, Pogue JM, Rybak MJ (2013) Implementation of an antimicrobial stewardship pathway with daptomycin for optimal treatment of methicillin-resistant Staphylococcus aureus bacteremia. Pharmacotherapy 33:3\u201310","journal-title":"Pharmacotherapy"},{"key":"582_CR28","first-page":"61","volume":"20","author":"KM Gawronski","year":"2015","unstructured":"Gawronski KM (2015) Successful use of daptomycin in a preterm neonate with persistent methicillin-resistant Staphylococcus epidermidis bacteremia. J Pediatr Pharmacol Ther 20:61\u201365","journal-title":"J Pediatr Pharmacol Ther"},{"key":"582_CR29","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1124\/pr.111.005769","volume":"65","author":"EI Nielsen","year":"2013","unstructured":"Nielsen EI, Friberg LE (2013) Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs. Pharmacol Rev 65:1053\u20131090","journal-title":"Pharmacol Rev"},{"key":"582_CR30","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/1440-1681.12195","volume":"41","author":"AH Salem","year":"2014","unstructured":"Salem AH, Zhanel GG, Ibrahim SA, Noreddin AM (2014) Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistant Staphylococcus aureus. Clin Exp Pharmacol Physiol 41:437\u2013443","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"582_CR31","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1128\/AAC.02192-12","volume":"57","author":"PA Moise","year":"2013","unstructured":"Moise PA, Amodio-Groton M, Rashid M, Lamp KC, Hoffman-Roberts HL, Yoon MJ et al (2013) Multicenter evaluation of the clinical outcomes of daptomycin with and without concomitant-lactams in patients with Staphylococcus aureus bacteremia and mild to moderate renal impairment. Antimicrob Agents Chemother 57:1192\u20131200","journal-title":"Antimicrob Agents Chemother"},{"key":"582_CR32","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1093\/jac\/dkx140","volume":"72","author":"PG Cojutti","year":"2017","unstructured":"Cojutti PG, Candoni A, Ramos-Martin V, Lazzarotto D, Zannier ME, Fanin R et al (2017) Population pharmacokinetics and dosing considerations for the use of daptomycin in adult patients with haematological malignancies. J Antimicrob Chemother 72:2342\u20132350","journal-title":"J Antimicrob Chemother"},{"key":"582_CR33","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1128\/AAC.02967-15","volume":"60","author":"SM Bhavnani","year":"2015","unstructured":"Bhavnani SM, Ambrose PG, Hammel JP, Rubino CM, Drusano GL (2015) Evaluation of daptomycin exposure and efficacy and safety endpoints to support risk-versus-benefit considerations. Antimicrob Agents Chemother 60:1600\u20131607","journal-title":"Antimicrob Agents Chemother"},{"key":"582_CR34","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1007\/s12325-015-0267-4","volume":"32","author":"RA Seaton","year":"2015","unstructured":"Seaton RA, Menichetti F, Dalekos G, Beiras-Fernandez A, Nacinovich F, Pathan R et al (2015) Evaluation of effectiveness and safety of high-dose daptomycin: results from patients included in the European Cubicin\u00ae outcomes registry and experience. Adv Ther 32:1192\u20131205","journal-title":"Adv Ther"},{"key":"582_CR35","first-page":"161","volume":"5","author":"K Yabuno","year":"2013","unstructured":"Yabuno K, Seki M, Miyawaki K, Miwa Y, Tomono K (2013) High-dose, short-interval daptomycin regimen was safe and well tolerated in three patients with chronic renal failure. Clin Pharmacol 5:161\u2013166","journal-title":"Clin Pharmacol"},{"key":"582_CR36","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.tube.2009.08.002","volume":"89","author":"NR Budha","year":"2009","unstructured":"Budha NR, Lee RB, Hurdle JG, Lee RE, Meibohm B (2009) A simple in vitro PK\/PD model system to determine time-kill curves of drugs against Mycobacteria. Tuberculosis (Edinb) 89:378\u2013385","journal-title":"Tuberculosis (Edinb)"},{"issue":"5","key":"582_CR37","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jiac.2015.02.001","volume":"21","author":"E As\u00edn-Prieto","year":"2015","unstructured":"As\u00edn-Prieto E, Rodr\u00edguez-Gasc\u00f3n A, Isla A (2015) Applications of the pharmacokinetic\/pharmacodynamic (PK\/PD) analysis of antimicrobial agents. J Infect Chemother 21(5):319\u2013329","journal-title":"J Infect Chemother"},{"key":"582_CR38","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.coph.2017.09.009","volume":"36","author":"M Trang","year":"2017","unstructured":"Trang M, Dudley MN, Bhavnani SM (2017) Use of Monte Carlo simulation and considerations for PK\u2013PD targets to support antibacterial dose selection. Curr Opin Pharmacol 36:107\u2013113","journal-title":"Curr Opin Pharmacol"}],"container-title":["Brazilian Journal of Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42770-021-00582-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s42770-021-00582-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42770-021-00582-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T02:11:08Z","timestamp":1636510268000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s42770-021-00582-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,2]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["582"],"URL":"https:\/\/doi.org\/10.1007\/s42770-021-00582-4","relation":{},"ISSN":["1517-8382","1678-4405"],"issn-type":[{"type":"print","value":"1517-8382"},{"type":"electronic","value":"1678-4405"}],"subject":[],"published":{"date-parts":[[2021,8,2]]},"assertion":[{"value":"22 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}